Cytovac

Focus: Cytovac is a Danish immunotherapy biotech focused on cell-based cancer treatments, specifically advancing ALECSAT across multiple oncology indications. The company operates as a pre-revenue biotech with no marketed products and a focused pipeline.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Cytovac

AI assessmentNot Hiring

No open roles listed right now. Follow Cytovac to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Alecsat

Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT01984658A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients

Phase 1

Help build intelligence for Cytovac

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline with ALECSAT in 7 active trials across high-value oncology indications (glioblastoma, breast cancer, prostate cancer, pancreatic cancer)
Cell-based immunotherapy platform positions the company at the intersection of emerging cancer treatment modalities with significant long-term upside
Denmark headquarters offers access to a biotech-friendly ecosystem with strong regulatory and funding infrastructure

Watch Out For

No active job openings and no employee count disclosed suggest a very small team with limited hiring velocity
Pre-revenue stage with no disclosed funding, cash position, or financial metrics raises sustainability and cash runway concerns
All pipeline programs remain in Phase 1/2 with no Phase 3 programs, meaning 5+ years minimum to potential regulatory approval and revenue

Generated by Claude from Cytovac's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ALECSAT

Hormone-refractory Prostate Cancer

Phase 1

Clinical Trials (1)

NCT00891345Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Phase 1

ALECSAT

Hormone-refractory Prostate Cancer

Phase 1

Clinical Trials (1)

NCT01422850Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Phase 1